0.94%| Prev Close: | 38.10 |
|---|---|
| Open: | N/A |
| Bid: | 38.25 x 300 |
| Ask: | 38.37 x 400 |
| 1y Target Est: | 44.88 |
| Beta: | 0.74 |
| Next Earnings Date: | N/A |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 36.63 - 46.00 |
| Volume: | 8,173 |
| Avg Vol (3m): | 4,306,230 |
| Market Cap: | 32.65B |
| P/E (ttm): | 16.93 |
| EPS (ttm): | 2.25 |
| Div & Yield: | 1.07 (2.80%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Teva Pharm quarterly profit falls less than expectedat Reuters(Thu 7:23AM EDT)
- Teva Reports First Quarter 2013 ResultsBusiness Wire(Thu 7:00AM EDT)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerPR Newswire(Wed, May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group(Wed, May 1)
- [$$] FDA Lowers Age Restriction on Plan Bat The Wall Street Journal(Tue, Apr 30)
- Teva confirms over-the-counter availability of Plan Bat theflyonthewall.com(Tue, Apr 30)
- InPlay: Teva Pharma confirms FDA approves over-the-counter availability of Plan B One-Step (levonorgestrel) tablet 1.5 mg for consumers 15 and overBriefing.com(Tue, Apr 30)
- FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and OverBusiness Wire(Tue, Apr 30)
- FDA Allows 'Morning After Pill' To Be Sold To Some Teenagers Without A Prescriptionat Forbes(Tue, Apr 30)
- Bayer Aims to Expand HealthCare PortfolioZacks(Tue, Apr 30)
- Forbes Earnings Preview: Teva Pharmaceutical Industriesat Forbes(Tue, Apr 30)
- OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentCNW Group(Tue, Apr 30)
- OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentPR Newswire(Tue, Apr 30)
- Teva Pharmaceutical Industries Ltd Stock Hold Recommendation Reiterated (TEVA)at TheStreet(Mon, Apr 29)
- Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy OfficerBusiness Wire(Mon, Apr 29)
Press Releases
- Teva Reports First Quarter 2013 ResultsBusiness Wire(Thu 7:00AM EDT)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerPR Newswire(Wed, May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group(Wed, May 1)
Reports
- TEVA: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- Trading Report for (TEVA). A detailed report, including free correlated market...Stock Traders Daily(May 2)
- ValuEngine Detailed Valuation Report for TEVAValuEngine, Inc.(May 2)